Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

BACKGROUND: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet
Hlavní autoři: Baselga, José, Bradbury, Ian, Eidtmann, Holger, Di Cosimo, Serena, de Azambuja, Evandro, Aura, Claudia, Gómez, Henry, Dinh, Phuong, Fauria, Karine, Van Dooren, Veerle, Aktan, Gursel, Goldhirsch, Aron, Chang, Tsai-Wang, Horváth, Zsolt, Coccia-Portugal, Maria, Domont, Julien, Tseng, Ling-Min, Kunz, Georg, Sohn, Joo Hyuk, Semiglazov, Vladimir, Lerzo, Guillermo, Palacova, Marketa, Probachai, Volodymyr, Pusztai, Lajos, Untch, Michael, Gelber, Richard D, Piccart-Gebhart, Martine
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705192/
https://ncbi.nlm.nih.gov/pubmed/22257673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)61847-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky